The Wall Street Journal (online registration required): The U.S. Food and Drug Administration said it approved Orexigen Therapeutics Inc.'s weight-loss treatment Contrave, the third such drug to receive the agency's approval in recent years.
Contrave has been approved as a treatment for chronic weight management in addition to a reduced-calorie diet and physical activity, the FDA said Wednesday in a...
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now